Martingale Asset Management L P Buys Shares of 24,712 Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)

Martingale Asset Management L P bought a new stake in shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTLFree Report) during the third quarter, Holdings Channel reports. The fund bought 24,712 shares of the company’s stock, valued at approximately $91,000.

A number of other institutional investors have also added to or reduced their stakes in the business. 49 Wealth Management LLC increased its position in Zentalis Pharmaceuticals by 81.7% during the 3rd quarter. 49 Wealth Management LLC now owns 22,558 shares of the company’s stock valued at $83,000 after purchasing an additional 10,145 shares during the period. Primecap Management Co. CA increased its position in Zentalis Pharmaceuticals by 21.6% during the 3rd quarter. Primecap Management Co. CA now owns 1,498,030 shares of the company’s stock valued at $5,513,000 after purchasing an additional 265,690 shares during the period. Intech Investment Management LLC purchased a new position in Zentalis Pharmaceuticals during the 3rd quarter valued at about $75,000. Connor Clark & Lunn Investment Management Ltd. boosted its holdings in shares of Zentalis Pharmaceuticals by 126.3% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 229,138 shares of the company’s stock valued at $843,000 after buying an additional 127,868 shares in the last quarter. Finally, Aigen Investment Management LP bought a new stake in shares of Zentalis Pharmaceuticals in the 3rd quarter valued at about $41,000.

Zentalis Pharmaceuticals Stock Up 0.9 %

ZNTL stock opened at $3.39 on Thursday. The firm has a 50 day moving average of $3.34 and a 200 day moving average of $4.65. The stock has a market capitalization of $241.57 million, a PE ratio of -1.36 and a beta of 1.84. Zentalis Pharmaceuticals, Inc. has a 52 week low of $2.66 and a 52 week high of $18.07.

Zentalis Pharmaceuticals (NASDAQ:ZNTLGet Free Report) last released its earnings results on Tuesday, November 12th. The company reported ($0.56) EPS for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.36. On average, equities research analysts expect that Zentalis Pharmaceuticals, Inc. will post -2.48 earnings per share for the current year.

Analyst Ratings Changes

ZNTL has been the topic of a number of recent analyst reports. Oppenheimer restated an “outperform” rating and issued a $20.00 price target on shares of Zentalis Pharmaceuticals in a report on Monday, September 16th. HC Wainwright restated a “buy” rating and issued a $20.00 price target on shares of Zentalis Pharmaceuticals in a report on Friday, November 15th. Wedbush upgraded shares of Zentalis Pharmaceuticals from an “underperform” rating to a “neutral” rating and set a $4.00 price target on the stock in a report on Monday, August 12th. Finally, Guggenheim lowered their price target on shares of Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating on the stock in a report on Friday, November 15th. Five research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $10.00.

Read Our Latest Stock Report on Zentalis Pharmaceuticals

Zentalis Pharmaceuticals Profile

(Free Report)

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.

See Also

Want to see what other hedge funds are holding ZNTL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTLFree Report).

Institutional Ownership by Quarter for Zentalis Pharmaceuticals (NASDAQ:ZNTL)

Receive News & Ratings for Zentalis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zentalis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.